Research Topics
| Domenic A SicaSummaryAffiliation: Virginia Commonwealth University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pharmacotherapy review: angiotensin-converting enzyme inhibitorsDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 7:485-8. 2005..This article is the first in a series describing important pharmacotherapeutic considerations of the individual drug classes used in the treatment of hypertension...
The risks and benefits of therapy with aldosterone receptor antagonist therapyDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
Curr Drug Saf 2:71-7. 2007..As such, steps should be taken to lessen the likelihood of its occurring if therapy is being contemplated with agents in this class...
Novel combinations in the treatment of hypertensionD A Sica
Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA, USA
Minerva Urol Nefrol 57:129-39. 2005..Such novel pharmacologic approaches offer useful options for treatment in the otherwise difficult to control hypertensive patient...
Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasisDomenic A Sica
Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0160, USA
Heart Fail Rev 10:23-9. 2005..This is more apt to occur with spironolactone due to the very long half-life of several of its active metabolites...
Gender and its effect in cardiovascular pharmacotherapeutics: recent considerationsDomenic A Sica
Departments of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology Virginia Commonwealth University Health System, Richmond, VA 23298, USA
Congest Heart Fail 11:163-6. 2005..The specific risk:benefit ratio for individual cardiovascular medications should be more routinely considered in the context of gender...
Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamicsDomenic A Sica
Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 7:21-6. 2005..Despite the potential for side effects with CCBs, their potent blood pressure-lowering effect makes them a prerequisite for blood pressure control in many patients...
Calcium channel blockers: a more expansive treatment roleDomenic A Sica
Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, USA
J Clin Hypertens (Greenwich) 7:2-4. 2005
Calcium channel blockers and the kidneyDomenic Sica
Section of Clinical Pharamcology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA
Clin Cornerstone 6:39-52. 2004..Non-DHP CCBs could potentially attenuate sympathetic activity and reduce protein excretion in patients with CKD...
Optimizing hypertension and vascular health: focus on ethnicityDomenic Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA
Clin Cornerstone 6:28-38. 2004..Calcium channel blockers are distinctive for their potent blood pressure-lowering effects, and novel strategies such as chronotherapeutic dosing of these agents has further improved upon the flexibility of their use...
New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE studyDomenic A Sica
Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Box 980160, MCV Station, Richmond VA 23298 0160, USA
J Clin Hypertens (Greenwich) 7:188-93. 2005..The neutral findings in this trial add a new wrinkle to the concept of class effect for cardiovascular protection with angiotensin-converting enzyme inhibitors in patients with coronary artery disease...
Current concepts of pharmacotherapy in hypertension. Carvedilol: new considerations for its use in the diabetic patient with hypertensionDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Box 980160, MCV Station, Richmond, VA 23298-0160, USA
J Clin Hypertens (Greenwich) 7:59-64. 2005
Current concepts of pharmacotherapy in hypertension: thiazide-type diuretics: ongoing considerations on mechanism of actionDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 6:661-4. 2004..Understanding these issues is important to the effective use of these compounds...
Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failureDomenic A Sica
Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
Congest Heart Fail 10:259-64. 2004..The frequency of such scrutiny should be patient-specific and based on the constellation of risk factors for hyperkalemia...
Hypertension, renal disease, and drug considerationsDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 6:24-30. 2004..A number of questions still remain unanswered in the pharmacotherapy of chronic kidney disease, including the optimal dose for these drugs as well as what represents the most favorable achieved blood pressure...
Diuretic-related side effects: development and treatmentDoemnic A Sica
Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, MCV Station Box 980160, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 6:532-40. 2004..This article reviews the commonly encountered side effects with the various diuretic classes. Where indicated, the mechanistic basis and treatment of such side effects is further discussed...
Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerationsDomenic A Sica
Departments of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertensiion, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 6:410-6. 2004..This review discusses the physiologic and non-physiologic basis for side effects with ACE inhibition...
ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trialsDomenic A Sica
Virginia Commonwealth University, MCV Station Box 980160, Richmond, VA 23298 0160, USA
Congest Heart Fail 10:160-4. 2004....
Clinical pharmacokinetics of losartanDomenic A Sica
Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, PO Box 980160, Richmond, VA 23298, USA
Clin Pharmacokinet 44:797-814. 2005..Losartan, like other angiotensin-receptor antagonists, is devoid of significant adverse effects...
The risks and benefits of aldosterone antagonistsDomenic A Sica
Division of Nephrology, Box 980160, MCV Station, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA
Curr Heart Fail Rep 2:65-71. 2005..Hyperkalemia should be considered as a possibility in any patient receiving these medications and as such is best addressed preemptively...
Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerationsDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 9:78-86. 2007..Additional outcomes trials, which are currently proceeding to their conclusion, may provide the necessary proof to support an expanded use of these 2 drug classes in combination...
Baroreflex activation for the treatment of hypertension: principles and practiceDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Virginia Commonwealth University Health System, Division of Nephrology, Box 980160, MCV Station, Richmond, VA 23298 0160, USA
Expert Rev Med Devices 3:595-601. 2006..Clinical trials designed to evaluate the efficacy and safety of this therapy in patients with resistant hypertension are now underway in both Europe and the USA...
Calcium channel blockers: monotherapy and dual therapy considerations in the treatment of hypertensionDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298 0160, USA
Am J Cardiovasc Drugs 7:1-3. 2007..provides data from INVEST (INternational VErapamil-Trandolapril STudy), which shows the particular utility of a CCB and ACE inhibitor combination in bringing elderly hypertensive patients with CAD to goal BP when monotherapy..
Interaction of grapefruit juice and calcium channel blockersDomenic A Sica
Department of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia, USA
Am J Hypertens 19:768-73. 2006..The calcium channel blocker and grapefruit juice interaction should be incorporated into the knowledge base of rational therapeutics for the prescribing physician...
Angiotensin receptor blockers: new considerations in their mechanism of actionDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 8:381-5. 2006..As the mechanistic basis for the action(s) of angiotensin receptor blockers more completely unfolds, added credence may ultimately be lent to widely touted and often overstated intraclass differences...
Hyponatremia and heart failure--treatment considerationsDomenic A Sica
Departments of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
Congest Heart Fail 12:55-60. 2006..Vasopressin receptor antagonists will redefine the treatment of heart failure-related hyponatremia and may possibly evolve as adjunct therapies to loop diuretics in diuretic-resistant patients...
Antihypertensive therapy and its effects on potassium homeostasisDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 8:67-73. 2006..Guidelines for the monitoring of serum potassium levels in the setting of antihypertensive therapy are at best makeshift and often drawn from the know-how of the treating physician...
Pharmacotherapy review: calcium channel blockersDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 8:53-6. 2006..Despite the sometimes discomforting side effects seen with calcium channel blocker therapy, their robust blood pressure-lowering effect makes them an important component of most multidrug regimens used for blood pressure control...
Alpha1-adrenergic blockers: current usage considerationsDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 7:757-62. 2005....
Pharmacotherapy review: Angiotensin receptor antagonistsDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 7:681-4. 2005..Results from a series of outcomes trials increasingly support the use of drugs in this class as cardioprotective and renoprotective agents in patients with heart failure, diabetic nephropathy, and post-myocardial infarction...
Hyponatremia and heart failure--pathophysiology and implicationsDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University, Richmond, VA 23298, USA
Congest Heart Fail 11:274-7. 2005..The recent availability of vasopressin receptor antagonists, however, offers a different approach to the management of this complex electrolyte disturbance, but one that is still evolving as to the scope of its clinical benefits...
Transdermal clonidine: therapeutic considerationsDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 7:558-62. 2005..The not infrequent development of a dermatitis, together with a substantially greater cost than oral clonidine, have been the major undoings for transdermal clonidine...
Pathologic basis and treatment considerations in chronic kidney disease-related hypertensionDomenic Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
Semin Nephrol 25:246-51. 2005....
Angiotensin-converting enzyme inhibitor use in the year 2005Domenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 7:8-11. 2005..The future of this drug class remains bright. Other drug classes, such as angiotensin receptor blockers, have narrowed-but not entirely closed-the outcomes gap that exists between these two drug classes...
Minoxidil: an underused vasodilator for resistant or severe hypertensionDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 6:283-7. 2004..There is, however, a place for minoxidil in the treatment of resistant hypertension especially in patients with advanced renal disease...
The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertensionDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 6:231-41. 2004..Propranolol CR is an effective antihypertensive formulation that may reduce blood pressure during the morning period of maximum cardiovascular risk...
What are the influences of salt, potassium, the sympathetic nervous system, and the renin-angiotensin system on the circadian variation in blood pressure?D A Sica
Department of Medicine and Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
Blood Press Monit 4:S9-S16. 1999..Additional studies of an integrative nature will be necessary to obtain more complete definition of the dynamic interplay between nutrition and various neurohumoral axes in determining how nocturnal blood pressure patterns are expressed...
Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapyDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
Congest Heart Fail 8:334-41, 345. 2002..The need to reduce renin-angiotensin aldosterone system activity in a heart failure patient would seem to justify the small risk of angioedema with ARB therapy in a patient having previously experienced ACE inhibitor-related angioedema...
Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate?D A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond 23298, USA
J Clin Hypertens (Greenwich) 4:441-5. 2002..Time and additional clinical experience with eplerenone will establish its safety profile and determine if the original label for this compound was correct...
Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?Domenic A Sica
Department of Medicine, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 4:375-80. 2002..Such justification might include the presence of heart failure or proteinuric nephropathic states among other considerations...
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patientDomenic A Sica
Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia, USA
Curr Opin Nephrol Hypertens 11:123-33. 2002..Polypharmacy and altered drug metabolism increase the risk of myotoxicity, albeit to an ill-defined degree, in this population. Many factors should enter into the choice of a statin in the multiply medicated renal failure patient...
Doxazosin and congestive heart failureDomenic A Sica
Department of Clinical Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
Congest Heart Fail 8:178-84. 2002..A valued member of our therapeutic armamentarium need not be laid entirely to rest; rather, doxazosin should now be viewed as a secondary or tertiary antihypertensive therapy pending a more complete review of the ALLHAT data...
Premature termination of clinical trials--lessons learnedD A Sica
Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 4:219-25. 2002..Early termination of a clinical trial can have important clinical implications and, in particular, can redirect patterns of clinical practice...
ACE inhibitors and stroke: new considerationsDomenic A Sica
Department of Medicine and Pharmacology, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 4:126-9, 133. 2002
Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment optionsDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 1060, USA
J Clin Hypertens (Greenwich) 4:52-7. 2002..An evidence-based therapeutic approach derived from these trials would argue for ARBs to be the foundation of therapy in the patient with type 2 diabetes and nephropathy...
Rhabdomyolysis and statin therapy: relevance to the elderlyDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
Am J Geriatr Cardiol 11:48-55. 2002..Physicians must take many factors into account when selecting a member of the HMG-CoA reductase inhibitor class, particularly as relates to their use in the multiply medicated elderly patient...
The importance of the sympathetic nervous system and systolic hypertension in patients with hypertension: benefits in treating patients with increased cardiovascular riskD A Sica
Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
Blood Press Monit 5:S19-25. 2000..This may provide an explanation for the differential effect on systolic blood pressure exhibited by this compound...
Disposition and safety of omapatrilat in subjects with renal impairmentD A Sica
Medical College of Virginia of Virginia Commonwealth University, Richmond 23298, USA
Clin Pharmacol Ther 68:261-9. 2000..Omapatrilat, a vasopeptidase inhibitor, preserves natriuretic peptides and inhibits the renin angiotensin aldosterone system by simultaneously inhibiting neutral endopeptidase and angiotensin-converting enzyme...
Class effects of angiotensin-converting enzyme inhibitorsD A Sica
Department of Clinical Pharmacology and Hypertension, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298 0160, USA
Am J Manag Care 6:S85-108; quiz S109-11. 2000..In addition, for some agents clinical trials that demonstrate decreased morbidity or mortality are currently lacking...
Pharmacokinetics and blood pressure response of losartan in end-stage renal diseaseD A Sica
Division of Clinical Pharmacology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298 0160, USA
Clin Pharmacokinet 38:519-26. 2000..Losartan is a selective angiotensin AT1 receptor antagonist currently employed in the management of essential hypertension. This compound is in common use in populations with renal failure and end-stage renal disease (ESRD)...
Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal diseaseD A Sica
Division of Clinical Pharmacology, Medical College of Virginia of Virginia Commonwealth University, Richmond 23298 0160, USA
Drug Saf 22:350-60. 2000....
The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal diseaseDomenic A Sica
Clinical Pharmacology and Hypertension, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia, 23298 0160, USA
J Renin Angiotensin Aldosterone Syst 3:247-54. 2002..These attributes would favour the increased use of ARBs in this population...
Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerationsDomenic A Sica
Division of Nephrology, Medical College of Virginia Commonwealth University, Richmond 23298, USA
Curr Opin Nephrol Hypertens 12:123-31. 2003..To characterize the pharmacokinetics and pharmacodynamics of the different calcium-channel blockers...
Hypertension and end-organ disease in African Americans: case presentationsDomenic A Sica
Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, 1101 East Marshall Street, Richmond, VA 23298-0160, USA
J Clin Hypertens (Greenwich) 6:48-53. 2004
EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?Domenic A Sica
Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 6:91-5. 2004....
Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practiceDomenic A Sica
Department of Medicine, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 5:414-20. 2003..Additional clarifying studies are required to establish whether specific patient subsets exist that might benefit from such combination therapy...
Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diureticsDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
Congest Heart Fail 9:287-92. 2003..However, the exact role of torsemide in the outpatient management of congestive heart failure remains to be determined...
Calcium channel blocker-related periperal edema: can it be resolved?Domenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 5:291-4, 297. 2003..Discontinuing the CCB and switching to an alternative antihypertensive therapy will resolve the edema...
Hyperkalemia, congestive heart failure, and aldosterone receptor antagonismDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Medical College of Virginia of Virginia Commonwealth University, MCBV Station Box 980160, Richmond, VA 23298 0160, USA
Congest Heart Fail 9:224-9. 2003....
Are current strategies for treating hypertension effective?Domenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 5:23-32. 2003....
The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?Domenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 5:159-67. 2003..It remains to be determined if this represents a class effect for all angiotensin-converting enzyme inhibitors...
Metolazone and its role in edema managementDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
Congest Heart Fail 9:100-5. 2003..The temptation should be avoided to simply reduce the doses of either metolazone or the loop diuretic as a means to controlling an active diuresis...
Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulationDomenic Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
Heart Dis 5:176-81. 2003..Bioavailability was similar for both formulations of propranolol. Propranolol CR exhibited appropriate pharmacokinetics for a chronotherapeutic approach to the treatment of hypertension...
Aldosterone-receptor antagonism and end-stage renal diseaseNiall McLaughlin
Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Box 980160, Richmond, VA 23298, USA
Curr Hypertens Rep 6:327-30. 2004..Eplerenone has not been studied in ESRD in a therapeutic or safety capacity. Additional studies are needed with these compounds in the ESRD population before their use can be considered safe...
Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African AmericansJackson T Wright
Department of Medicine, Division of Hypertension, Case Western Reserve University, Cleveland, Ohio, USA
Am J Hypertens 17:734-42. 2004....
Centrally acting antihypertensive agents: an updateDomenic A Sica
Division of Nephrology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
J Clin Hypertens (Greenwich) 9:399-405. 2007..Escalating doses of drugs in this class often give rise to salt and water retention, in which case diuretic therapy becomes a valuable adjunctive therapy...
Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. IntroductionDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, Virginia 23298, USA
Am J Cardiol 98:1L-4L. 2006
Angiotensin-converting enzyme inhibition-emerging pulmonary issues relating to coughDomenic A Sica
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0160, USA
Congest Heart Fail 12:223-6. 2006..These new pulmonary observations in patients afflicted with an ACE inhibitor-related cough should revive interest in this bothersome side effect...
Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeatsDomenic A Sica
Medical College of Virginia, Virginia Commonwealth University, Box 980160 MCV Station, Richmond, VA 23298 0160, USA
Drugs 62:443-62. 2002..If made truly cost-competitive, it will gain an increasing share of the hypertensive market. If not, market forces will relegate it to a secondary role for hypertension treatment...
The Losartan Intervention for Endpoint Reduction (LIFE) trial-have angiotensin-receptor blockers come of age?Domenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond 23298, USA
J Clin Hypertens (Greenwich) 4:301-5. 2002..The results of this trial are both interesting and relevant to what is an expanding use of angiotensin-receptor blockers in the hypertensive population...
Angiotensin receptor blockers and drug-drug interactionsDomenic A Sica
Virginia Commonwealth University, Division of Nephrology, Box 980160, MCV Station Medical College of Virginia, Richmond, Virginia 23298 0160, USA
Expert Opin Drug Saf 4:139-40. 2005..Moreover, this drug class is devoid of relevant class-specific side effects. These features provide some of the basis for the excellent tolerance of drugs in this class...
Sodium and water retention in heart failure and diuretic therapy: basic mechanismsDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298 0160, USA
Cleve Clin J Med 73:S2-7; discussion S30-3. 2006....
Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous systemSiddhartha S Ghosh
Division of Nephrology, VCU Medical Center, Virginia Commonwealth University, MCV Station, Box 980160, Richmond, VA, 23298 0160, USA
Pediatr Nephrol 24:367-77. 2009..Furthermore, AKT (activated via alpha1A receptors), as well as increased alpha1A receptors and their agonist NE, might contribute to the observed hypertrophy...
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in BlacksJanice G Douglas
Case Western Reserve University, Department of Medicine, Room W-165, 10900 Euclid Ave, Cleveland, Ohio 44106, USA
Arch Intern Med 163:525-41. 2003
Use of enoxaparin in patients with chronic kidney disease: safety considerationsDonald F Brophy
Department of Pharmacy, Virginia Commonwealth University/Medical College of Virginia Campus, Richmond, Virginia 23298-0533, USA
Drug Saf 30:991-4. 2007
Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight lossHarvey J Sugerman
Division of General Trauma Surgery, Department of Surgery, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 0519, USA
Ann Surg 237:751-6; discussion 757-8. 2003..To evaluate the preoperative relationships of hypertension and diabetes mellitus in severe obesity and the effects of gastric bypass (GBP)-induced weight loss...
The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitorsDomenic A Sica
Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
J Renin Angiotensin Aldosterone Syst 3:66-71. 2002..Additional clarifying studies are needed to establish whether specific patient subsets exist that might benefit from such combination therapy...
Acute phosphate nephropathy following colonoscopy preparationDaniel E Carl
Department of Medicine, Division of Nephrology, Box 980160, MCV Station, Virginia Commonwealth University, Richmond, Virginia 23298-0160, USA
Am J Med Sci 334:151-4. 2007
Rationale for combination therapy in the treatment of hypertensionDomenic A Sica
Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0160, USA
J Renin Angiotensin Aldosterone Syst 3:63-5. 2002..Like most matters in the clinical sector the approach to a disease in this case hypertension should remain highly individualised and cognisant of what can be significant cost considerations...
Angiotensin-converting enzyme inhibitor-related angioedema: recognition and treatmentMaureen P Flattery
Pauley Heart Center, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
Prog Cardiovasc Nurs 22:47-51. 2007
Importance of potassium in cardiovascular diseaseD A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia Virginia Commonwealth University, Richmond, VA 23298, USA
J Clin Hypertens (Greenwich) 4:198-206. 2002..Because of the complexity of this topic, issues of hyperkalemia will be addressed in a forthcoming manuscript...
